Michael Abidin, MD
Otolaryngology/Facial Plastic Surgery · Alexandria, VANPI 1568465912
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations.
Across 216 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$986
- Regeneron Healthcare Solutions, Inc.$681
- GSK$551
- Acclarent, Inc$531
- Takeda Pharmaceuticals U.S.A., Inc.$394
- Alk-abello, Inc$268
- plus $2K from 29 others
Across 1 payment — averaging $4070.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siesta Medical, Inc.$4K
Across 7 payments — averaging $1871.43 each. An ownership or investment interest held by the physician or an immediate family member.
- Siesta Medical, Inc.$13K
What the payments were for
- Food & beverage$5,18999%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 40 | $986 |
| Regeneron Healthcare Solutions, Inc. | 31 | $681 |
| GSK | 28 | $551 |
| Acclarent, Inc | 17 | $531 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $394 |
| Alk-abello, Inc | 16 | $268 |
| Stryker | 3 | $131 |
| Novartis | 6 | $130 |
| AbbVie | 4 | $124 |
| Merz North America, Inc. | 1 | $123 |
| Shire North American Group Inc | 2 | $114 |
| Aerin Medical Inc. | 5 | $112 |
| Grifols USA, LLC | 5 | $103 |
| Optinose US, Inc. | 5 | $92 |
| Greer Laboratories, Inc. | 3 | $89 |
| Supernus Pharmaceuticals, Inc. | 4 | $80 |
| Biocryst US Sales Co., LLC | 2 | $65 |
| Neurent Medical Limited | 1 | $63 |
| Intersect ENT, Inc. | 2 | $57 |
| Pfizer | 3 | $55 |
| Integra Lifesciences Corporation | 2 | $54 |
| Lundbeck LLC | 2 | $53 |
| Johnson & Johnson(2 entities) | 2 | $49 |
| Genentech USA, Inc. | 2 | $46 |
| Sanofi-aventis U.S. LLC | 1 | $41 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Merck | 2 | $33 |
| Amgen | 1 | $26 |
| Watermark Medical, Inc. | 1 | $20 |
| Galderma Laboratories, L.p. | 1 | $20 |
| Davol Inc. | 1 | $20 |
| Vertex | 1 | $19 |
| Smith+Nephew | 1 | $17 |
| Olympus America Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acclarent Navwire$150
- NUCALA$104
- HYQVIA$101
How this compares
Too few otolaryngology/facial plastic surgery providers in Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 27 | $113,221 |
| DuleraMometasone/Formoterol | 11 | $3,831 |
| Ipratropium Bromide | 65 | $1,943 |
| Ofloxacin | 48 | $1,464 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 11 | $1,259 |
| Fluocinolone Acetonide Oil | 19 | $878 |
| Cevimeline Hcl | 13 | $851 |
| Modafinil | 20 | $763 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 85 | $706 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $558 |
| Clarithromycin | 30 | $457 |
| Gabapentin | 49 | $409 |
| Montelukast Sodium | 44 | $330 |
| Sumatriptan Succinate | 17 | $325 |
| Hydroxychloroquine Sulfate | 15 | $289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckDulera | $33 | $3,83111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few otolaryngology/facial plastic surgery providers in Virginiaon file to place this against a meaningful peer group, so we don't.
Other otolaryngology/facial plastic surgery in Alexandria
- Michael ArmstrongRichmond$11K
- Christopher TsangFairfax$4K
- Matthew HubbardAbingdon$3K
- Brian DeutschNorfolk$2K
- Stephen BaneWoodbridge$2K
- Nariman DashFredericksburg$2K
- Nima VahidiRichmond$2K
- John LieserFredericksburg$1K
- Alan BurkeRichmond$1K
- Jacob KuperstockFairfax$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.